Zevra Therapeutics Stock Hub ($ZVRA): MIPLYFFA Launch, EMA Rejection and Celiprolol Phase 3

Q2 2026 Deep Dive: Better U.S. Launch Evidence, but Europe Still Defines the Regulatory Skew

The Q2 print materially strengthens the evidence that MIPLYFFA has become a commercially meaningful U.S. rare-disease franchise. Total net revenue was $39.663 million, compared with $36.220 million in Q1 and $25.881 million in Q2 2025. MIPLYFFA contributed $30.2 million, up 22.8% sequentially and approximately 40.5% year over year. That acceleration is more informative than total-company growth because it comes from the asset that now carries most of Zevra’s recurring value after the SDX divestiture.

The patient funnel also advanced, but it should be interpreted carefully. Fourteen prescription enrollment forms were received during Q2, versus nine during Q1, taking the cumulative count to 184. A prescription enrollment form begins the access and benefits process; it does not equal a dispensed prescription, an active reimbursed patient or durable persistence. Payer access remained unchanged at 69% of covered lives, so Q2’s revenue improvement appears to reflect stronger execution within an already established access footprint rather than a fresh coverage step-up.

The European read-through is mixed. Global EAP enrollment increased by ten patients to 132, confirming that the program remained active through June 30. Net EAP reimbursement nevertheless fell 11.8% sequentially to $9.0 million. Patient growth and revenue do not move one-for-one because country mix, collection timing, reimbursement terms, gross-to-net adjustments and clawback accounting can differ. The decline does not prove that access is contracting, but it reinforces why EAP revenue should not be capitalized as a fixed annuity while the CHMP re-examination is pending.

EPS quality screen: Q2 GAAP earnings are more representative of current operations than either Q1 2026, which included the $43.3 million SDX-sale gain and debt-payoff effects, or Q2 2025, which included the PRV sale, impairment and inventory charges. Even so, the $6.4 million non-cash fair-value charge makes GAAP net income lower than the operating result. The cleanest recurring signal is the $16.8 million operating profit, not a mechanical annualization of either GAAP or adjusted EPS.

Evidence posture: the earnings release, Form 8-K and Q2 Form 10-Q were reviewed. The filing confirms $23.2 million of positive operating cash flow for the first six months of 2026, an $18.6 million aggregate EAP clawback liability and no ATM sales through June 30. No official text transcript was available in the retrieved source set, so this hub does not attribute call-only statements from unofficial transcripts.

The Merlintrader View: Watchlist-Quality Fundamentals, but Europe Is No Longer a Clean Upside Option

Zevra has enough operating substance for a full Stock Hub because its investment case contains four separate analytical layers: a marketed rare-disease franchise, a disputed cross-regulatory evidence package, a second late-stage clinical program and an unusually liquid balance sheet. That is more durable than a one-day news article. The company is also approaching an earnings event that can update sales, patient enrollment, EAP economics and the response strategy to the CHMP opinion.

The positive side is straightforward. U.S. MIPLYFFA revenue reached $30.2 million in Q2, payer coverage remained 69% of covered lives, the company reported 184 prescription enrollment forms since launch, and management has a $260.2 million liquidity cushion. An enrollment form starts the benefits-investigation process; it is not the same as an active, reimbursed patient. MIPLYFFA also received an Orange Book patent listing that the company says can protect the franchise until November 2041, subject to the usual caveat that patent listing is not the same as guaranteed freedom from challenge. Celiprolol addresses a severe rare disease with no FDA-approved disease-specific therapy and is being studied under a Special Protocol Assessment.

The caution side is equally important. MIPLYFFA is still a concentrated launch in an ultra-rare population. The easy-to-find or pent-up patient cohort can make early rare-disease launches look stronger than their steady-state new-patient flow. Europe cannot now be valued as a routine label expansion. The re-examination may uphold the refusal, and no new data can simply be added during that procedure. Celiprolol is event-driven and had only three confirmed qualifying events at June 30, so its timing remains difficult to forecast. Finally, the company has an unused $75 million ATM and broad shelf capacity even though near-term financing need appears low.

MIPLYFFA in the United States: The Commercial Foundation Is Already Visible

MIPLYFFA is an oral capsule taken three times daily and is approved in combination with miglustat for the treatment of neurological manifestations of NPC in adults and children aged two years and older. FDA approved it on September 20, 2024, making it the first FDA-approved treatment for NPC. Four days later, FDA approved IntraBio’s AQNEURSA, a stand-alone levacetylleucine therapy for adults and pediatric patients weighing at least 15 kilograms. The two products therefore entered the market at nearly the same time but with different labels, evidence packages and positioning.

The pivotal MIPLYFFA evidence came from a randomized, double-blind, placebo-controlled study involving 50 children and adolescents aged two to 18 years. FDA’s label-relevant population included 39 patients receiving concomitant miglustat. The main measure was change in a five-domain NPC Clinical Severity Scale covering ambulation, swallowing, cognition, speech and fine motor skills. FDA accepted the evidence in the combination-with-miglustat population, while EMA later concluded that the overall efficacy case was not sufficiently robust. This difference in regulatory interpretation is now the defining scientific issue for the company.

Commercial execution has been strong enough to make MIPLYFFA a real franchise. Zevra reported $87.4 million of MIPLYFFA U.S. net revenue in 2025. In Q1 2026, net sales reached $24.6 million; in Q2 they increased to $30.2 million, up 22.8% sequentially and approximately 40.5% from Q2 2025. The company received 14 new prescription enrollment forms during Q2 and 184 since launch, while payer coverage remained 69% of covered lives. Those forms initiate benefits investigation and should not be equated one-for-one with active or paying patients. Management estimates that roughly 900 people in the United States live with NPC, of whom approximately 300 to 350 are diagnosed or treated.

Those prevalence estimates are company framing, not a guaranteed commercial denominator. The investable question is not how many patients theoretically live with NPC; it is how many are diagnosed, clinically appropriate, reimbursed, initiated and persistent on therapy. In ultra-rare disease, patient identification can create substantial growth, but every lost patient or delayed authorization matters. Q2 results should therefore be read through prescription forms, covered lives, starts, persistence and gross-to-net quality rather than product revenue alone.

MIPLYFFA Lifecycle Management: Patent Protection and Infant Data

On June 8, 2026, Zevra announced the Orange Book listing of U.S. Patent No. 11,707,456 for MIPLYFFA. The patent expires on November 19, 2041. The company also has a separate patent-term extension application pending for U.S. Patent No. 11,045,460, which currently expires in 2029. The listing materially improved the company’s public IP narrative and contributed to several analyst target increases before the CHMP news.

Patent protection should be treated carefully. An Orange Book listing establishes a formal patent position associated with the approved drug and can shape generic challenge timing, but it does not guarantee that every claim will survive litigation or block all forms of competition until 2041. Regulatory exclusivity and patent protection are also different legal concepts. Investors should value the estate as an advantage while leaving room for challenge risk.

On June 23, Zevra announced publication of an open-label pediatric substudy involving five children aged 12 to under 24 months at enrollment. Arimoclomol was used with concomitant miglustat for up to 36 months. The company reported that treatment was generally well tolerated, with no new safety signals, and that pharmacokinetics were consistent with older pediatric populations. Developmental outcomes varied, which Zevra attributed to disease heterogeneity.

The substudy is useful scientific evidence but should not be promoted as if it were a registrational program. Five patients in an open-label design cannot establish efficacy or guarantee a label expansion below age two. Zevra has described the data as supporting exploration of earlier treatment, but it had not announced a formal supplemental NDA timetable as of July 24. The correct valuation treatment is modest lifecycle optionality.

Financial Snapshot: Q2 Shows Positive Core Operations Without a Transaction Gain

Zevra reported Q2 2026 net revenue of $39.663 million, up 53.3% from $25.881 million a year earlier and 9.5% from Q1. MIPLYFFA U.S. net revenue represented $30.2 million, or about 76% of the total. Global EAP net reimbursement was $9.0 million, about 23%. Past-due AZSTARYS royalties and other reimbursements contributed $0.3 million, while OLPRUVA contributed $0.2 million.

Cost of product revenue was $1.525 million, excluding $0.316 million of intangible amortization. R&D expense was $4.486 million and SG&A was $16.559 million. Operating income reached $16.777 million. Unlike Q1, Q2 operating income did not depend on the $43.3 million SDX-sale gain; unlike Q2 2025, the current quarter did not include a PRV-sale gain, the OLPRUVA impairment or an inventory write-down.

GAAP net income was $8.752 million, or $0.14 per basic and diluted share, after a $6.408 million non-cash fair-value charge related to warrant and CVR liabilities and $4.042 million of income-tax expense. Zevra presented company-defined adjusted net income of $15.2 million, or $0.25 per diluted share. That non-GAAP measure helps isolate operations but should not be treated as audited recurring earnings.

Operating cash flow was positive $23.174 million for the first half of 2026, versus an $11.823 million outflow in the first half of 2025. The filing cautions that near-term operating cash flow could still be minimally positive or negative and that recent positivity is not guaranteed. A single profitable half-year should therefore not be converted mechanically into a permanent cash-generation rate.

Bull Case: U.S. MIPLYFFA Becomes a Durable Rare-Disease Franchise

The constructive scenario begins with continued MIPLYFFA growth in the United States. New prescription enrollment forms remain steady, payer coverage expands beyond 69%, diagnosed-but-untreated patients convert and persistence remains high. Q2 and subsequent quarters demonstrate that the launch is not only pent-up demand from the easiest-to-find patients.

In Europe, Zevra keeps most EAP patients on treatment and reimbursement remains economically meaningful while re-examination proceeds. A successful re-examination would reopen a commercial population that management estimates at approximately 1,100 European NPC patients, with potentially higher diagnosis rates than in the United States. Even without immediate reversal, stable EAP access would protect a significant revenue stream.

Celiprolol adds a second leg if FDA dialogue produces a credible acceleration path or DiSCOVER enrollment and event accumulation improve. The large cash balance funds the program without forcing a dilutive financing and gives Zevra flexibility to add another rare-disease asset. Long-dated MIPLYFFA patent protection supports franchise durability.

In this scenario, the market begins valuing Zevra as an early commercial rare-disease company with two major assets rather than a one-product company recovering from a European setback.